AbbVie's etentamig beat older salvage on response and progression-free survival in Phase 3 CERVINO. The harder question is whether a single step-up and monthly intravenous schedule can loosen the REMS-and-hospitalization architecture that still gates approved BCMA T-cell engagers.
Newsletter
Pipeline, markets, policy, and science. Once a week.
After encouraging early pancreatic data, demand for Alpha DaRT helped quadruple its IMPACT study from 12 patients to 48 as the company moves toward a pivotal trial.
Suzetrigine beat placebo on SPID48 in both pivotal acute-pain trials, then failed the superiority test against hydrocodone/acetaminophen, including a statistically significant loss in bunionectomy.
The $2.3 billion licensing deal for Phase 1 asset HM17321 targets a core drawback of current GLP-1 therapies: the loss of lean skeletal muscle alongside fat.